ClinicalTrials.gg

Program

HRS-4729

A development code. Also written as “HRS-4729 Injection”, “HRS-4729 Injection;” and “HRS-4729 injection”.

In Jiangsu HengRui Medicine's pipeline, GLP-1/GIP/ GCG. Its studies are mostly in Obesity · Diabetes Mellitus, Type 2 · Fatty Liver, led by Jiangsu HengRui Medicine.

Furthest: phase 2, since Jun 16, 20265 company-led studies, 4 open or runningNext primary completion: Mar 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Jiangsu HengRui Medicine54 open or runningphase 2since Jun 16, 2026Dec 31, 2024Mar 2027phase 2 · NCT07690826
  • Named in Jiangsu HengRui Medicine’s own pipeline as HRS-4729, phase 2, as of Jul 31, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Dec 31, 2024First study: phase 1 study in OverweightFirst studyNCT06762600 · 102 enrolled · China
  2. Jun 16, 2026Phase 2 study in Metabolic Dysfunction-Associated Steatohepatitis (MASH)Phase 2 reachedNCT07660848 · 160 planned · China
  3. Jul 1, 2026Phase 2 study in OverweightNCT07690826 · 252 planned · China
  4. Aug 17, 2026Phase 1 study in OverweightNCT07807059 · 32 planned · China
  5. Sep 22, 2026Phase 2 study in Diabetes Mellitus, Type 2NCT07843862 · 240 planned · China

Ahead

  1. Mar 2027Primary completion: phase 2 study in OverweightNCT07690826
  2. Mar 15, 2027Primary completion: phase 1 study in OverweightNCT07807059
  3. Apr 2027Primary completion: phase 2 study in Diabetes Mellitus, Type 2NCT07843862
  4. Mar 2028Primary completion: phase 2 study in Metabolic Dysfunction-Associated Steatohepatitis (MASH)NCT07660848

TargetBeta

“GLP-1/GIP/ GCG”the company's pipeline, read by Claude · source

Other programs on the same three targets

ProgramCompanyFurthest phaseStudies
retatrutideruleEli Lillyphase 333
UBT251The United Laboratories Internationalphase 312

Studies

All 5 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07843862Diabetes Mellitus, Type 2 · China2Not yet recruitingApr 2027240
NCT07807059Overweight · China1RecruitingMar 15, 202732
NCT07690826Overweight · China2Not yet recruitingMar 2027252
NCT07660848Metabolic Dysfunction-Associated Steatohepatitis (MASH) · China2RecruitingMar 2028160
NCT06762600Overweight · China1CompletedMar 12, 2026102

How it is read

Names in the registry

  • “HRS-4729 Injection”, 5 entries
  • “HRS-4729 Injection;”, 3 entries
  • “HRS-4729”, 1 entry
  • “HRS-4729 injection”, 1 entry

Codes read as this program: HRS4729.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.